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Summary
Background The ORACLE II trial compared the use of erythromycin and/or amoxicillin–clavulanate (co-amoxiclav) 
with that of placebo for women in spontaneous preterm labour and intact membranes, without overt signs of 
clinical infection, by use of a factorial randomised design. The aim of the present study—the ORACLE Children 
Study II—was to determine the long-term eﬀ ects on children after exposure to antibiotics in this clinical 
situation.
Methods We assessed children at age 7 years born to the 4221 women who had completed the ORACLE II study and 
who were eligible for follow-up with a structured parental questionnaire to assess the child’s health status. Functional 
impairment was deﬁ ned as the presence of any level of functional impairment (severe, moderate, or mild) derived 
from the mark III Multi-Attribute Health Status classiﬁ cation system. Educational outcomes were assessed with 
national curriculum test results for children resident in England.
Findings Outcome was determined for 3196 (71%) eligible children. Overall, a greater proportion of children whose 
mothers had been prescribed erythromycin, with or without co-amoxiclav, had any functional impairment than did 
those whose mothers had received no erythromycin (658 [42·3%] of 1554 children vs 574 [38·3%] of 1498; odds ratio 
1·18, 95% CI 1·02–1·37). Co-amoxiclav (with or without erythromycin) had no eﬀ ect on the proportion of children 
with any functional impairment, compared with receipt of no co-amoxiclav (624 [40·7%] of 1523 vs 608 [40·0%] of 
1520; 1·03, 0·89–1·19). No eﬀ ects were seen with either antibiotic on the number of deaths, other medical conditions, 
behavioural patterns, or educational attainment. However, more children whose mothers had received erythromycin 
or co-amoxiclav developed cerebral palsy than did those born to mothers who received no erythromycin or no 
co-amoxiclav, respectively (erythromycin: 53 [3·3%] of 1611 vs 27 [1·7%] of 1562, 1·93, 1·21–3·09; co-amoxiclav: 
50 [3·2%] of 1587 vs 30 [1·9%] of 1586, 1·69, 1·07–2·67). The number needed to harm with erythromycin was 
64 (95% CI 37–209) and with co-amoxiclav 79 (42–591). 
Interpretation The prescription of erythromycin for women in spontaneous preterm labour with intact membranes 
was associated with an increase in functional impairment among their children at 7 years of age. The risk of cerebral 
palsy was increased by either antibiotic, although the overall risk of this condition was low.
Funding UK Medical Research Council.
Introduction
Preterm birth is associated with later disabilities among 
surviving children that pose major challenges for public 
health and education; these problems increase in 
frequency as gestational age at birth decreases,1 such 
that around 25% of babies born before 26 weeks of 
gestation have serious disability2 and many children 
without serious disability have learning or behavioural 
diﬃ  culties.3,4 
Observational evidence suggests that perinatal intra-
uterine infection or inﬂ ammation might have a role in 
the causation of 13–22% of cases of spontaneous 
preterm labour (SPL)5,6 and infection or inﬂ am mation 
have been implicated in the genesis of neonatal lung 
disease7 and brain injury.8 Despite a number of 
randomised trials of the use of antibiotics for women 
with SPL and intact membranes, no clear evi dence of 
beneﬁ t has been found and there is some evidence to 
suggest that such treatment might be associated with 
increased neonatal mortality.9
ORACLE II10 enrolled women who presented with SPL 
and intact membranes and assessed the use of 
amoxicillin–clavulanate (co-amoxiclav) 375 mg, or 
erythromycin 250 mg, or both, or placebo, four times a 
day for 10 days or until birth (whichever was soonest), by 
use of a factorial randomised design. Neither antibiotic 
was associated with any improvement in neonatal 
mortality or morbidity. In view of the poor predictive 
validity of neonatal morbidity after preterm birth for 
childhood outcome, it is important to determine whether 
there are long-term sequelae associated with the use, or 
not, of these antibiotic treatments in women presenting 
with SPL. We report the results of the ORACLE Children 
Study II (OCS II), which was designed to assess the 
long-term outcomes for children born in the UK to 
women enrolled in the original ORACLE II trial. 
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Methods
Participants 
OCS II began in 2002 and sought follow-up information 
for children at 7 years of age who were born to the 
6241 women who completed the ORACLE II trial.10 
Tracing and contact of participants in the follow-up study 
are described in detail in the accompanying paper.11
The West Midlands Multi-centre Research and Ethics 
Committee (MREC) approved the study and the 
University of Leicester, UK, sponsored the OCS. 
Oversight was provided by an independent trial steering 
committee and data monitoring committee, both of 
which met annually. Those involved in tracing and data 
entry remained blind to the allocated treatment. All data 
to assess health and educational outcomes were double 
entered and subject to validation and logic checks. 
Data collection
Data were collected with a parent-completion postal 
questionnaire, which consisted of the the Health Utilities 
Index (HUI),12 from which the Multi-Attribute Health 
Status (MAHS) is derived, the Strengths and Diﬃ  culties 
Questionnaire,13 and speciﬁ c questions on respiratory 
symptoms,14 hospital admissions, convulsions, other 
speciﬁ c medical conditions, and demographic data. 
The primary outcome was deﬁ ned as the presence of 
any level of functional impairment (severe, moderate, or 
mild) derived from the mark III MAHS classiﬁ cation 
system12 within any of the individual attributes of vision, 
hearing, speech, ambulation, dexterity, emotion, 
cognition, or pain. Each attribute has either ﬁ ve or six 
deﬁ ned levels of impairment, ranging from normal 
function to severe dysfunction.15 These have been 
classiﬁ ed further into none, mild, moderate, or severe 
levels of severity for the individual attributes from the 
standard algorithms available within the HUI coding/
procedure manual. The overall level of functional 
impairment was determined by their worst score on any 
attribute. Sensitivity analyses were also done based on 
the HUI3 multi-attribute utility scores of overall health-
related quality of life,16 which became available after this 
study had begun.
Secondary outcomes were the presence of three or 
more abnormal attributes derived from the MAHS 
classiﬁ cation system and the degree of functional 
impairment (severe, moderate, mild, none) within the 
individual domains; the number of deaths between trial 
entry and discharge and age 7 years; overall and subscale 
scores derived from the parent-completed Strengths and 
Diﬃ  culties Questionnaire; the frequency of speciﬁ c 
medical conditions including CNS problems (cerebral 
palsy, ﬁ ts/seizures, hydrocephalus with a shunt), 
respiratory problems (wheezing, medication for asthma), 
hospital admission (both in the last year and for chest 
problems), diabetes, bowel disorders, and developmental 
problems (attention deﬁ cit hyperactivity disorder derived 
from the Strengths and Diﬃ  culties Questionnaire17 or 
parent report), and other development problems.
We used results from national curriculum tests (key 
stage one), done at 7 years of age to assess the children’s 
educational attainment for residents in England.18 Such 
tests are not routinely done in other parts of the UK. At 
key stage one, all children are awarded a level for each of 
reading, writing, and mathematics. These include levels 
three and four, which are above average, level two (the 
average level awarded to 60–70% of pupils, and which is 
also subdivided into three sublevels), and below level 
two, which includes children who attained level one, 
those who were working towards level one, or who were 
not entered by the teacher. For all eligible children in 
England, key stage one level data were provided 
anonymously by the UK Department for Children, 
Schools and Families (DCSF), categorised by treatment 
group.
Statistical analysis
The size of the study was predeﬁ ned by the number of 
women recruited to the ORACLE II trial. The indicative 
power calculation in the protocol noted that about 
4500 children were expected to be eligible for the follow-
up study. About 3·1% of the children in the any 
erythromycin group were expected to have three or 
6241 women completed ORACLE II trial  
4221 women eligible for OCS follow-up  
4473 children 
54 women excluded
       14 protocol violations
       40 lost to follow-up
6295 women entered into ORACLE II trial 
3196 children (71%) whose outcome is known:
            3052 (68%) parents returned a questionnaire
               121 (3%) health of child known from GPs
                                  and parents
                 23 (1%) children died 
1277 children whose outcome is not known:
              65 emigrated, no contact made
            149 lost to follow-up, no contact made
              80 opted out by parents after initial contact
            983 no response to questionnaire or
                     other contact
2020 women excluded
                98 women excluded due to death of child in ORACLE II trial
            1877 women randomised outside the UK
                 45 women withdrew before start of OCS   
Figure 1: Flowchart for SPL group through ORACLE II and extended follow-up in OCS II
*133 babies died during ORACLE II. However, only 98 women were excluded because a number had a multiple 
birth. Of the 133 babies, 86 were singletons, 26 multiple births where all babies died (10 sets of twins and two sets 
of triplets), and 21 were multiple births with live siblings.
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more abnormal attributes using the MAHS scale.12 
Assuming an 85% response rate, this gave 80% power 
(with two-tailed α=0·05) to detect a prevalence of three 
or more abnormal attributes in the no erythromycin 
group of 5% (a relative diﬀ erence between the two 
groups of 38%).
Odds ratios with 95% CI are presented for primary and 
secondary outcomes in the groups receiving co-amoxiclav 
(any co-amoxiclav: either with or without erythromycin) 
and erythromycin (any erythromycin: either with or 
without co-amoxiclav) separately. Odds ratios approxi-
mate relative risks when the risk is low.19 Logistic models 
with terms indicating allocation to co-amoxiclav and 
erythromycin and an interaction term, corresponding to 
the ORACLE II trial’s factorial design, were also ﬁ tted.20 
Since our ﬁ ndings were generally not altered when 
interaction terms were included, for simplicity they have 
not been included in models presented in the main 
tables, but they are available on the internet. Multiple 
births were treated as being independent in the analyses, 
Erythromycin and 
co-amoxiclav
Erythromycin only Co-amoxiclav only Placebo
At entry to ORACLE II
Number of women 755 764 744 728
Maternal age (years) 26·9 (22·9–31·1) 27·2 (23·0–31·7) 26·5 (22·8–30·9) 27·2 (23·7–31·4)
Gestational age at trial entry (days) 220 (201–233) 219 (202–233) 217 (200–232) 219 (201–233)
Multiple births 44 (5·8%) 45 (6·8%) 49 (6·6%) 47 (6·5%)
Maternal antibiotics in the postnatal period 76 (10·1%) 89 (11·7%) 86 (11·6%) 111 (15·3%)
Short-term outcomes of ORACLE II
Number of babies 795 816 792 770
Birth within 48 h of trial entry 87 (10·9%) 93 (11·4%) 83 (10·5%) 96 (12·5%)
Birth within 7 days of trial entry 120 (15·1%) 141 (17·3%) 130 (16·4%) 127 (16·5%)
Gestational age (days) 267 (247–278) 266 (245–278) 266 (245–278) 266 (245–277)
Birthweight (g) 2980 (2300–3460) 2940 (2269–3395) 2970 (2287–3460) 2920 (2290–3420)
Sex (male) 416 (52·3%) 460 (56·4%) 400 (50·5%) 436 (56·6%)
 Admission to neonatal unit 232 (29·2%) 242 (29·7%) 233 (29·4%) 234 (30·4%)
 Ventilated 78 (9·8%) 66 (8·1%) 73 (9·2%) 71 (9·2%)
 Respiratory distress syndrome 91 (11·5%) 75 (9·2%) 79 (10·0%) 80 (10·4%)
 Supplementary oxygen at 28 days 39 (4·9%) 33 (4·0%) 34 (4·3%) 38 (4·9%)
 Positive blood culture 24 (3·0%) 12 (1·5%) 16 (2·0%) 16 (2·1%)
 Necrotising enterocolitis (suspected or proven) 13 (1·6%) 8 (1·0%) 14 (1·8%) 5 (0·7%)
 Abnormal cerebral ultrasonography 15 (1·9%) 10 (1·2%) 8 (1·0%) 12 (1·6%)
At entry to OCS II
Ethnic origin (white) 718 (90·3%) 737 (90·3%) 716 (90·4%) 682 (88·6%)
Smoking in family 375 (47·2%) 372 (45·6%) 358 (45·2%) 332 (43·1%)
Damp or mould problems 72 (9·1%) 51 (6·3%) 43 (5·4%) 37 (4·8%)
Family history of asthma 414 (52·1%) 418 (51·2%) 415 (52·4%) 382 (49·6%)
Child’s age at completion of questionnaire (years) 6·97 (6·91–7·06) 6·97 (6·91–7·07) 6·98 (6·91–7·08) 6·97 (6·91–7·06)
Child’s age at the start of the academic year they sat key 
stage one tests (years)
6·42 (6·25–6·75) 6·42 (6·17–6·67) 6·50 (6·25–6·67) 6·42 (6·17–6·67)
Data are n (%) or median (IQR).
Table 1: Characteristics of the responders in the SPL group
  Any erythromycin 
(N=1554)
No erythromycin 
(N=1498)
OR (95% CI) Any co-amoxiclav 
(N=1532)
No co-amoxiclav 
(N=1520)
OR (95% CI)
None 896 (57·7%) 924 (61·7%) Ref 908 (59·3%) 912 (60·0%) Ref
Any functional impairment 658 (42·3%) 574 (38·3%) 1·18 (1·02–1·37) 624 (40·7%) 608 (40·0%) 1·03 (0·89–1·19) 
Mild 372 (23·9%) 319 (21·3%) 1·20 (1·01–1·43) 349 (22·8%) 342 (22·5%) 1·02 (0·86–1·22)
Moderate 185 (11·9%) 162 (10·8%) 1·18 (0·94–1·48) 176 (11·5%) 171 (11·3%) 1·03 (0·82–1·30)
Severe 101 (6·5%) 93 (6·2%) 1·12 (0·83–1·51) 99 (6·5%) 95 (6·3%) 1·05 (0·78–1·41)
Three or more abnormal  
attributes
131 (8·4%) 149 (9·9%) 0·83 (0·65–1·07) 147 (9·6%) 133 (8·8%) 1·11 (0·87–1·42)
Table 2: Overall level of functional impairment at age 7 years from the mark III Multi-Attribute Health Scale in children whose mothers had SPL
www.thelancet.com   Vol 372   October 11, 2008 1321
Articles
but sensitivity analyses based on randomly selecting one 
child were also done.21
Data from the Strengths and Diﬃ  culties Questionnaire 
were classiﬁ ed as normal, borderline, or abnormal. Odds 
ratios and CI for proportions with borderline or abnormal 
scores are presented. Models with interaction terms are 
also ﬁ tted as above.
Subgroup analyses were done as speciﬁ ed in the 
protocol, relating to multiple and singleton pregnancies, 
and gestational age subgroups used at the time of 
randomisation (<32 weeks’ gestation and <28 weeks’ 
gestation). 
Relative risks and 95% CI for key stage one educational 
data were obtained from Poisson regression models, 
adjusting for test year. Because of restricted information 
available from the anonymous summary of these data 
supplied by the DCSF, sensitivity and subgroup analyses 
were not possible for these data.
Most of the outcomes presented, including the primary 
outcome of the follow-up study, can only be assessed in 
surviving children. Thus the analyses presented are not 
based on the intention-to-treat principle (ie, by analysis 
of outcomes in all those entered into the trial). However, 
the absolute risk of death was low, limiting any potential 
bias that might be introduced by undertaking the analyses 
of surviving children only, as pre-speciﬁ ed in the study 
protocol. There were no clear diﬀ erences in the numbers 
of deaths in each of the study groups at the end of the 
ORACLE II trial, but we present sensitivity analyses 
using a composite death or any functional impairment 
outcome to conﬁ rm the limited eﬀ ect of including deaths 
in the analyses. 
Informal allowance for the large number of comparisons 
undertaken is made in interpreting the results 
throughout.22
Outcomes for children not assessed may diﬀ er from 
outcomes for those who were assessed.23 To explore this, 
we investigated diﬀ erences between responders and non-
responders for a variety of factors: treatment group, 
short-term maternal and neonatal outcomes, ethnicity, 
indices of deprivation from ONS derived from post code, 
and for those children in England, educational 
attainment.
Role of the funding source
The study sponsors had no involvement in the study 
design; collection, analysis, and interpretation of the 
data; in the writing of the report; and in the decision to 
submit the paper for publication. DJ and KP had full 
access to all the data. SK had ﬁ nal responsibility for the 
decision to submit for publication. 
Results
Of the 4473 UK children eligible for follow-up, outcome 
was known for 3196 (71%): 3052 (68%) parents returned a 
questionnaire, data were collected from telephone 
interview or the family doctor for 121 (3%) children 
(included in the analysis of speciﬁ c medical conditions), 
and 23 (1%) died (ﬁ gure 1). Women were unaware of their 
treatment allocation, with the exception of three people 
Any erythromycin No erythromycin OR (95% CI) Any co-amoxiclav No co-amoxiclav OR (95% CI)
Number of women 2219 2145 2158 2206
Number of children 2375 2279 2304 2350
Stillbirths 20 (0·8%) 24 (1·1%) 0·80 (0·44–1·45) 20 (0·9%) 24 (1·0%) 0·85 (0·47–1·54)
Deaths in ﬁ rst year 61 (2·6%) 41 (1·8%) 1·44 (0·96–2·14) 49 (2·1%) 53 (2·3%) 0·94 (0·63–1·39) 
Deaths after ﬁ rst year 5 (0·2%) 5 (0·2%) 0·97 (0·28–3·34) 6 (0·3%) 4 (0·2%) 1·53 (0·43–5·42) 
Total deaths 86 (3·6%) 70 (3·1%) 1·19 (0·86–1·63) 75 (3·3%) 81 (3·4%) 0·94 (0·68–1·30)
Total death or any functional impairment 744 (31·3%) 644 (28·3%) 1·16 (1·02–1·31) 699 (30·3%) 689 (29·3%) 1·05 (0·93–1·19) 
Total death or three or more abnormal attributes 217 (9·1%) 219 (9·6%) 0·95 (0·78–1·15) 222 (9·6%) 214 (9·1%) 1·06 (0·87–1·30)
Total death or cerebral palsy 139 (5·9%) 97 (4·3%) 1·40 (1·07–1·82) 125 (5·4%) 111 (4·7%) 1·16 (0·89–1·50)
Table 3: Deaths in ORACLE II and during OCS II in children whose mothers had SPL
 Erythromycin and 
co-amoxiclav (N=769)
OR (95% CI)* Erythromycin 
only (N=785)
OR (95% CI)* Co-amoxiclav 
only (N=763)
OR (95% CI)* Double placebo 
(N=735)
OR 
(95% CI)*
None 444 (57·7%) 0·82 (0·66–1·00) 452 (57·6%) 0·81 (0·66–1·00) 464 (60·8%) 0·93 (0·75–1·14) 460 (62·6%) Ref
Any functional impairment 325 (42·3%) 1·22 (1·00–1·51) 333 (42·4%) 1·23 (1·00–1·51) 299 (39·2%) 1·08 (0·88–1·33) 275 (37·4%) Ref
Mild 181 (23·5%) 1·24 (0·96–1·60) 191 (24·3%) 1·29 (1·00–1·65) 168 (22·0%) 1·10 (0·85–1·42) 151 (20·5%) Ref 
Moderate 91 (11·8%) 1·22 (0·88–1·70) 94 (12·0%) 1·24 (0·89–1·72) 85 (11·1%) 1·09 (0·78–1·53) 77 (10·5%) Ref
Severe 53 (6·9%) 1·17 (0·77–1·77) 48 (6·1%) 1·04 (0·68–1·59) 46 (6·0%) 0·97 (0·63–1·49) 47 (6·4%) Ref
Three or more abnormal attributes 72 (9·4%) 0·92 (0·66–1·30) 59 (7·5%) 0·73 (0·51–1·04) 75 (9·8%) 0·97 (0·69–1·37) 74 (10·1%) Ref
Odds ratios are comparisons with the double placebo group.
Table 4: “Inside the table” analysis of overall level of functional impairment at age 7 years from the mark III Multi-Attribute Health Scale in children whose mothers had SPL
For more on indices of 
deprivation see http://www.
neighbourhood.statistics.gov.uk
1322 www.thelancet.com   Vol 372   October 11, 2008
Articles
who requested this information before returning data for 
this study. Only 0·6% of data within returned question-
naires were missing. Full key stage one level data were 
available for 3239 (95%) of the 3394 children in England 
who had been entered for the tests by 2007. The 
characteristics of the responders to the question naires 
were broadly similar to the total population enrolled in the 
ORACLE II trial (table 1), but mothers in the double 
placebo group were less likely to be white, and received 
more postnatal antibiotics than those in the other groups 
(table 1).
Children whose outcome was unknown had younger 
mothers and had less neonatal morbidity (webtable 1), 
and at least for those in England, were from more 
deprived areas than those whose outcome was known 
(webtable 2). More English children whose outcome was 
un known scored below level two in key stage one tests 
and were less likely to be white than were those whose 
outcome was known (webtable 2).
More children whose mothers had received any 
erythromycin had any functional impairment than did 
those whose mothers received no erythromycin (table 2). 
The proportion of children categorised as having moderate 
or severe functional impairment, or with three or more 
abnormal attributes, did not vary markedly between 
treatment groups, but the proportion of children with mild 
functional impairment was higher in the any erythromycin 
group than in the no erythromycin group (table 2). 
Findings were similar for the composite outcome of death 
or any functional impairment (table 3). Sensitivity analyses 
based on the HUI3 multi-attribute utility function16 lead to 
broadly similar results (webtable 3).
By contrast, there was no diﬀ erence between children 
whose mothers had received any co-amoxiclav and those 
whose mothers had received no co-amoxiclav in 
terms of the proportion of children with any func-
tional impairment; in the categories of mild, moderate, 
severe, or three or more abnormal attributes; or when 
functional impairment was combined with death (table 2 
and table 3). 
These ﬁ ndings were supported when ﬁ tting a logistic 
model with terms for erythromycin, co-amoxiclav, and an 
interaction between the two drugs (webtable 4); there was 
no evidence of an interaction in eﬀ ects between the drugs 
(webtable 4). Results were consistent when missing data 
were assumed to correspond to a functional impairment 
(data not shown). Table 4 presents the results of the four 
treatment groups “inside the table” of the factorial trial;24 
again, increases in functional impairment were seen 
with the prescription of erythromycin. 
The number of deaths (table 3; webtable 5), behaviour 
(table 5; webtable 6), educational attainment (table 6), 
and non-neurological conditions (table 7; webtable 7) did 
not diﬀ er between children whose mothers had received 
any erythromycin, compared with those whose mothers 
had received no erythromycin, except for more chil dren 
presenting with bowel disorders if their mother had 
received any erythromycin. Receipt of co-amoxiclav 
seemed to have no eﬀ ect on any of these out comes, 
compared with receipt of no co-amoxiclav (tables 3, 5–7).
However, more children whose mothers had received 
any erythromycin or whose mothers had received any 
co-amoxiclav had cerebral palsy than did those whose 
mothers had received no erythromycin or no 
 Any erythromycin 
(N=1554)
No erythromycin 
(N=1498)
OR (95% CI) Any co-amoxiclav 
(N=1532)
No co-amoxiclav 
(N=1520)
OR (95% CI)
Emotional symptoms 327 (21·0%) 330 (22·0%) 0·94 (0·79–1·12) 341 (22·3%) 316 (20·8%) 1·09 (0·92–1·30)
Conduct problems 480 (30·9%) 420 (28·0%) 1·15 (0·98–1·34) 454 (29·6%) 446 (29·3%) 1·01 (0·87–1·18)
Hyperactivity 424 (27·3%) 415 (27·7%) 0·98 (0·84–1·15) 418 (27·3%) 421 (27·7%) 0·98 (0·84–1·15)
Peer problems 405 (26·1%) 391 (26·1%) 1·00 (0·85–1·17) 396 (25·8%) 400 (26·3%) 0·98 (0·83–1·15)
Prosocial behaviour 122 (7·9%) 99 (6·6%) 1·20 (0·91–1·59) 112 (7·3%) 109 (7·2%) 1·02 (0·78–1·34)
Overall (total diﬃ  culties) 384 (24·7%) 363 (24·2%) 1·03 (0·87–1·21) 385 (25·1%) 362 (23·8%) 1·07 (0·91–1·27)
Impact on families 334 (21·5%) 292 (19·5%) 1·13 (0·95–1·35) 312 (20·4%) 314 (20·7%) 0·98 (0·82–1·17)
Data are number of children scoring borderline or abnormal on each scale (%).
Table 5: Behaviour at age 7 years from the Strengths and Diﬃ  culties Questionnaire in children whose mothers had SPL
 Any erythromycin 
(N=1641)
No erythromycin 
(N=1598)
RR (95% CI) * Any co-amoxiclav 
(N=1608)
No co-amoxiclav 
(N=1631)
RR (95% CI)*
Reading 377 (23·0%) 367 (23·0%) 1·00 (0·96–1·04) 366 (22·8%) 378 (23·2%) 0·99 (0·95–1·03)
Writing 413 (25·2%) 413 (25·8%) 1·00 (0·97–1·04) 395 (24·6%) 431 (26·4%) 0·99 (0·95–1·02)
Maths 239 (14·6%) 225 (14·1%) 0·99 (0·96–1·03) 230 (14·3%) 234 (14·3%) 0·99 (0·95–1·03)
Data are number of children failing to achieve level 2 or higher (%). Overall relative risks (RR) and 95% CI are from Poisson models for level achieved adjusting for test year, 
2002–07. National norms for 2002–07 have been standardised by the numbers of children in the OCS II cohort each year, and suggest that we would expect the following 
percentages of children to fail to achieve level 2 or above: reading 15%, writing 18%, maths 12%. *No evidence of overdispersion when these Poisson models are ﬁ tted.
Table 6: Educational attainment in reading, writing and mathematics, for England only, for children whose mothers had SPL
See Online for webtables 1–7
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co-amoxiclav, respectively (table 7). A logistic model with 
erythromycin, co-amoxiclav, and treatment interaction 
terms suggested that there was no evidence of an 
interaction between the two antibiotics (webtable 7). 
However, the study is underpowered to test the 
interaction term and thus further examination of results 
“inside the table” was done.24 These analyses suggest 
that more children who developed cerebral palsy had 
been born to mothers who had received both antibiotics 
(35 children) than to mothers who received erythromycin 
only (18 children), co-amoxiclav only (15 children), or 
double placebo (12 children). Although there is evidence 
of an excess risk in the both antibiotics group compared 
with double placebo (OR 2·91, 1·50–5·65), there is 
insuﬃ  cient power to exclude an excess risk in those 
exposed to either drug alone (erythromycin alone: OR 
1·42, 95% CI 0·68–2·98; co-amoxiclav alone: 1·22, 
0·57–2·62).
In this study the number needed to harm in the any 
erythromycin group was 64 (95% CI 37–209) and in the 
any co-amoxiclav group was 79 (42–591). In view of the 
unexpected excess of cerebral palsy associated with 
antibiotic prescription, further exploratory analyses of 
the characteristics of the children with cerebral palsy, 
and of risk factors for this condition, were done. The 
excess of cases of cerebral palsy was not oﬀ set by a lower 
number of deaths in the any erythromycin group: death 
and cerebral palsy were both increased in the any 
erythromycin group (table 3). There is no evidence that 
the children reported with cerebral palsy in the combined 
antibiotic group were more severely aﬀ ected than were 
those in the other treatment groups (table 8). Analysis of 
 Any erythromycin 
(N=1611)
No erythromycin 
(N=1562)
OR (95% CI) Any co-amoxiclav 
(N=1587)
No co-amoxiclav 
(N=1586)
OR (95 % CI)
CNS problems
Cerebral palsy 53 (3·3%) 27 (1·7%) 1·93 (1·21–3·09) 50 (3·2%) 30 (1·9%) 1·69 (1·07–2·67)
Seizures 149 (9·2%) 116 (7·4%) 1·27 (0·99–1·64) 144 (9·1%) 121 (7·6%) 1·21 (0·94–1·56)
On prescribed medication 27 (1·7%) 17 (1·1%) 1·55 (0·84–2·85) 22 (1·4%) 22 (1·4%) 1·00 (0·55–1·81)
Hydrocephalus with shunt 2 (0·1%) 3 (0·2%) 0·65 (0·11–3·87) 4 (0·3%) 1 (0·1%) 4·01 (0·45–35·87)
Developmental problems
ADHD from SDQ or parental report 120 (7·4%) 116 (7·4%) 1·00 (0·77–1·31) 128 (8·1%) 108 (6·8%) 1·20 (0·92–1·57)
Other developmental problems 10 (0·6%) 15 (1·0%) 0·64 (0·29–1·44) 8 (0·5%) 17 (1·1%) 0·47 (0·20–1·09)
Respiratory problems
Wheezing in last year 295 (18·3%) 295 (18·9%) 0·96 (0·81–1·15) 291 (18·3%) 299 (18·9%) 0·97 (0·81–1·16)
Medication for chest problems  in 
last year
262 (16·3%) 280 (17·9%) 0·89 (0·74–1·07) 257 (16·2%) 285 (18·0%) 0·88 (0·73–1·06) 
Prednisolone 29 (1·8%) 33 (2·1%) 0·85 (0·51, 1·41) 28 (1·8%) 34 (2·1%) 0·82 (0·49, 1·36)
Oxygen 22 (1·4%) 22 (1·4%) 0·97 (0·53–1·76) 17 (1·1%) 28 (1·8%) 0·60 (0·33–1·11)
Relievers 235 (14·6%) 259 (16·6%) 0·86 (0·71–1·04) 244 (15·4%) 250 (15·8%) 0·97 (0·80–1·18)
Preventers  182 (11·3%) 199 (12·7%) 0·87 (0·70–1·08) 186 (11·7%) 195 (12·3%) 0·95 (0·76–1·17)
Hospital admission
Admission to hospital in last year 243 (15·1%) 202 (12·9%) 1·20 (0·98–1·46) 220 (13·9%) 225 (14·2%) 0·97 (0·80–1·19)
Admission for chest problems 32 (2·0%) 38 (2·4%) 0·81 (0·51–1·31) 33 (2·1%) 37 (2·3%) 0·89 (0·55–1·43)
Diabetes
Diabetes 0 (0·0%) 2 (0·1%) .. 2 (0·1%) 0 (0·0%) ..
Bowel disorders
All bowel problems 64 (4·0%) 38 (2·4%) 1·66 (1·10–2·49) 54 (3·4%) 48 (3·0%) 1·13 (0·76–1·68)
Bowel stoma 24 (1·5%) 13 (0·8%) 1·80 (0·91–3·55) 21 (1·3%) 16 (1·0%) 1·32 (0·68–2·53)
Other bowel problems 40 (2·5%) 25 (1·6%) 1·57 (0·95–2·59) 33 (2·1%) 32 (2·0%) 1·03 (0·63–1·69) 
ADHD=attention deﬁ cit hyperactivity disorder. SDQ=Strength and Diﬃ  culties Questionnaire.
Table 7: Medical conditions reported by parents of children at age 7 years in those whose mothers had SPL
 Erythromycin and 
co-amoxiclav (N=35)
Erythromycin 
only (N=18)
Co-amoxiclav 
only (N=15)
Double placebo 
(N=12)
None 1 (2·9%) 1 (5·6%) 1 (6·7%) 0 (0·0%)
Any functional impairment 33 (94·3%) 16 (88·9%) 12 (80·0%) 12 (100·0%)
Mild 4 (11·4%) 2 (11·1%) 0 (0·0%) 1 (8·3%)
Moderate 10 (28·6%) 3 (16·7%) 1 (6·7%) 3 (25·0%)
Severe 19 (54·3%) 11 (61·1%) 11 (73·3%) 8 (66·7%)
Children scoring severe functional impairment do so in the following domains 
Ambulation 18 (51·4%) 9 (50·0%) 7 (46·7%) 5 (41·7%)
Dexterity 6 (17·1%) 6 (33·3%) 8 (53·3%) 3 (25·0%)
Cognition 5 (14·3%) 0 (0·0%) 4 (26·7%) 4 (33·3%)
Pain 5 (14·3%) 3 (16·7%) 3 (20·0%) 4 (33·3%)
Functional impairment outcomes are not available for four children for whom a questionnaire was not returned 
(one in both antibiotics group, one in erythromycin only group, and two in the co-amoxiclav only group).
Table 8: Functional impairment outcomes of the children with cerebral palsy whose mothers had SPL  
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individual HUI attributes did not show any treatment 
eﬀ ects; the attributes for which children with cerebral 
palsy were most commonly categorised as having severe 
functional impairment were ambulation, dexterity, 
cognition, and pain (table 8).
Children with cerebral palsy were more likely to be 
have been born to women recruited at earlier gestations, 
and to be born sooner after the enrolment of the mother 
than were children without cerebral palsy (webtable 8). 
Maternal antibiotic prescription for postnatal infection 
was more likely for children with cerebral palsy than for 
those without; the duration of time from trial entry to 
birth was more likely to be less than 1 day or between 
1 and 10 days for children with cerebral palsy than for 
those without (webtable 8). Babies with cerebral palsy 
were more likely to be male and to be admitted to a 
neonatal intensive care unit than were those without, 
and, as anticipated, were at increased risk of associated 
neonatal morbidity (webtable 8). 
By contrast with the cerebral palsy group as a whole, 
more detailed “inside the table” comparisons show more 
children with cerebral palsy whose mothers had received 
both antibiotics were entered into the trial between 
28 and 32 weeks of gestation than were those whose 
mothers received one or other of the antibiotics, or who 
had received placebo (webtable 8). Further examination 
of this group (24 children) showed an excess in the both 
antibiotic group of those that had cervical dilation 0 to 
1 cm at recruitment, who received the randomised 
treatment for 10 days, and who were born after 32 weeks 
(webtable 9).
Subgroup analyses for multiple versus singleton births 
and for gestation above and below 28 and 32 weeks at 
randomisation were pre-planned (ﬁ gure 2). The increased 
risk of functional impairment observed after receipt of 
any erythromycin is most clearly apparent in singleton 
births and those children who were born at low gestational 
age, with sampling variation being larger in the small 
multiple birth and other gestational age subgroups. 
Adjustment for maternal baseline, social class, and other 
factors did not substantially alter the treatment eﬀ ects 
noted (data not shown). For further analyses, see http://
www2.le.ac.uk/Members/drj/supplementary-materials-
for-papers.
Discussion
In this long-term follow-up of children whose mothers 
took part in the ORACLE II trial of antibiotics for preterm 
labour in the presence of intact membranes, we found an 
unexpected increase in the number of children with any 
functional impairment who were exposed to 
erythromycin. Furthermore, we found an increased 
prevalence of cerebral palsy (as reported by parents) 
associated with treatment with either antibiotic; there is 
some evidence to suggest that there is an additive eﬀ ect 
in the children of mothers who received both antibiotics. 
Although formal evidence of an interaction between the 
two antibiotics is lacking, and the power of the study to 
detect such interactions is low, the excess of children 
with cerebral palsy born to mothers who received both 
antibiotics is clear enough to suggest that this should not 
be dismissed as a chance result of multiple testing. While 
a Bonferroni correction24 (based on a family size of ten 
main comparisons per treatment, as in table 7) might 
suggest that chance cannot be ruled out as an explanation, 
there are a number of features that suggest it would be 
Figure 2: Subgroup analyses for overall functional impairment in children whose mothers had SPL
Overall
Multiple births
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Gestation <28 weeks
Gestation >28 weeks
 Gestation <32 weeks
Gestation >32 weeks
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unwise to dismiss the excess of cerebral palsy as a chance 
ﬁ nding. These include a potential dose-response 
relationship (if the subgroup receiving both antibiotics is 
regarded as having received a higher dose of antibiotic), 
biological plausibility, and possibly speciﬁ city to cerebral 
palsy. There is also evidence to suggest that the treatment 
eﬀ ect seen here is not simply a result of a spuriously low 
rate of cerebral palsy in the placebo group—stratiﬁ ed 
data from a register of children with cerebral palsy in 
four counties in the UK suggest that 7·5 cases would 
have been expected, compared with the 12 cases 
observed.25 These results provide strong evidence for the 
importance of childhood follow-up of perinatal and 
neonatal trials and interventions.
We chose to obtain proxy information about the 
children from parents because the size of the study 
population made individualised assessment both 
impractical and prohibitively expensive. Where possible 
we used well validated and standardised instruments,12,13 
but use of a questionnaire could mean it was not possible 
to detect more subtle diﬀ erences between treatment 
groups, nor has it been possible to conﬁ rm the ﬁ ndings. 
In spite of not having face-to-face contact, we achieved an 
acceptable follow-up rate of 71% by maintaining regular 
contact with the women originally entered into the trial. 
Although we attempted to minimise non-response, 
disadvantaged groups are over-represented in the non-
responders. There is evidence to suggest that outcomes 
for children assessed with diﬃ  culty might diﬀ er from 
those assessed with ease.23 However, there was no 
evidence of diﬀ erential response bias and most women 
remained unaware of their treatment allocation. Despite 
the response rate being lower than that assumed in the 
initial power calculation, the increased prevalence of 
functional impairment resulted in power being increased 
overall. 
The results of this study must be viewed within the 
clinical context of this group of women. First, the accurate 
diagnosis of SPL was and remains imperfect, as many 
women who present with painful preterm uterine 
contractions do not give birth preterm. This was the case 
in this study, where almost 64% of women who were 
entered into the ORACLE II trial gave birth after 37 weeks 
of gestation. Second, the proportion of women who had 
subclinical intrauterine infection at the time of 
randomisation is not known; however, it will probably 
have been low (13–22%5,6). 
Why receipt of antibiotics increased the risk of 
functional impairment and cerebral palsy in a population 
at low risk of intrauterine infection is unclear. We suggest 
a number of pathways, although others will no doubt 
emerge. Length of exposure to antibiotics for this group 
of women was fairly long, with 15–20% giving birth 
within 7 days.10 An episode of preterm labour which 
settles could genuinely reﬂ ect an infective episode, where 
maternal defences—facilitated by antibiotics—overcome 
the insult, thus prolonging pregnancy, but not necessarily 
resolving the associated intrauterine and fetal inﬂ am-
mation. A continuing inﬂ ammatory environment could 
have led to fetal brain injury and thereby cerebral palsy. 
Alternatively, cerebral palsy could have resulted from a 
direct eﬀ ect of the antibiotics themselves; erythromycin, 
for example, has signiﬁ cant eﬀ ects on the cardiovascular 
system—eg, arrythmias—which could have led to 
cerebral ischaemic events and thereby cerebral palsy.26 It 
is also possible that the episode of SPL was not associated 
with infection, but rather with other pathologies within 
the so-called preterm parturition syndrome,6 which 
might have been exacerbated by the antibiotics by as yet 
undetermined mechanisms.
The results of this study add weight to the argument 
that we should be vigilant about interfering with systems 
we poorly understand in the absence of beneﬁ t. For 
example, there is little known about the eﬀ ect of 
antibiotics on early patterns of microbial colonisation of 
newborn children, which might have important, long-
lasting consequences for early human development.27 
Whatever the causal pathway, the ﬁ ndings in our study, 
together with concerns about the potential increase in 
neonatal mortality,9 support the opinion that antibiotics 
are not advisable in SPL without clinical signs of 
infection. Indeed, in the UK, women are not routinely 
prescribed antibiotics if they have intact membranes, 
although there are no national guidelines; likewise, in 
the USA, antibiotics are not recommended in preterm 
labour.28 Nonetheless, it is critical that women with 
evidence of clinical infection are treated with antibiotics, 
since clinical chorioamnionitis remains an important 
cause of maternal, fetal, and neonatal death. The results 
of this study should not lead to fewer women with overt 
signs of maternal or fetal infection receiving treatment. 
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